HF
ACOR

HRT Financial’s Acorda Therapeutics ACOR Stock Holding History

HRT Financial’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-626
Closed -$7K – 3622
2023
Q1 		$7K Buy
+626
New +$10.4K ﹤0.01% 2279
2022
Q3 		– Sell
-1,966
Closed -$18K – 3756
2022
Q2 		$18K Buy
+1,966
New +$34.9K ﹤0.01% 2626
2020
Q1 		– Sell
-578
Closed -$141K – 1487
2019
Q4 		$141K Buy
578
+43
+8% +$10.8K 0.01% 990
2019
Q3 		$184K Buy
+535
New +$291K 0.01% 1174

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

HRT Financial's ACOR Position: Q2 2023 in Review

HRT Financial sold out of Acorda Therapeutics (ACOR) in Q2 2023, closing a stake of 626 shares — an estimated $7K sold.

HRT Financial first reported a position in ACOR in Q3 2019 and held it in 4 quarters. The position peaked at $184K in Q3 2019. 15 funds tracked by Wall St. Rank hold ACOR as of Q2 2023.

  • HRT Financial reported no remaining Acorda Therapeutics position as of Q2 2023 after selling out during the quarter.
  • HRT Financial sold 626 Acorda Therapeutics shares in Q2 2023, an estimated $7K.
  • HRT Financial first reported a position in Acorda Therapeutics in Q3 2019 and held it in 4 quarters.
  • HRT Financial's Acorda Therapeutics position peaked at $184K in Q3 2019.
  • 15 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2023.

Based on HRT Financial's 13F filing for Q2 2023, filed 11 Aug 2023.